Navigation Links
Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man

New York, NY (PRWEB) May 20, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a South Dakota man who alleges that use of the diabetes drug medication Actos (pioglitazone) caused bladder cancer. The suit was filed on April 30, 2013, in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-0888), where it is one of thousands of cases pending in the Actos multidistrict litigation (In Re: Actos (Pioglitazone) Products Liability Litigation, MDL No. 6:11-md-2299). Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee in the litigation. Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff began taking Actos in January 2009. He developed bladder cancer in May 2011, allegedly due to the side effects of Actos. At this time, he stopped taking the medication. The lawsuit alleges that the Defendants were aware that taking the diabetes drug could lead to an increased risk of bladder cancer, but failed to disclose this information to the Plaintiff, his doctor and other consumers. The Plaintiff is suing for extensive pain and suffering, severe emotional distress.

According to the U.S. Food and Drug Administration (FDA), taking Actos for one year may significantly increase your risk of bladder cancer. The safety label for Actos was updated in June 2011 to reflect this risk*. The warning was based on the results of an ongoing 10-year study by Kaiser Permanente. *(

Studies have continued to suggest that Actos can increase the risk of bladder cancer. For instance, the May 31, 2012 issue of the British Medical Journal** found that Actos users were twice as likely to develop bladder cancer after two years. In July 3, 2012, the Canadian Medical Association Journal*** found that patients taking the medication were 22 percent more likely to get bladder cancer. **( ***(

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Monterey Bay Nutraceuticals Now Taking Advance Orders Online
2. Garcinia Cambogia Select - A Miracle Weight Loss Supplement Taking the Industry by Storm; Exclusive News by Health Care Supplementz
3. University Finds that People Trade Off Healthy Habits Due to Time Constraints, Suggesting that Just Taking Supplements Like Prescopodene May Help With Weight Loss
4. Taking cholesterol-lowering drugs may also reduce the risk of dying from prostate cancer: Study
5. Multicenter study confirms low testosterone in 84 percent of lung cancer patients taking crizotinib
6. MedMar Healing Center, Taking Clone Pre-Orders for High-Quality Medical Marijuana Strains
7. Poor Health Literacy Keeps Patients From Taking Meds
8. Diet Can Lower Blood Pressure As Much As Taking A Medication, From The March 2013 Harvard Men's Health Watch
9. First of its kind study in Canada looks at who is taking aspirin to prevent heart attack or stroke
10. Increasing Number of Doctors Recommend Taking Gene-Eden-VIR
11. Test-taking may improve learning in people of all ages
Post Your Comments:
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent Pharma Solutions, the leading ... health and global clinical supply services, today announced that Dr. Christine Milligan, Global ... Asia Conference, to be held at the InterContinental Seoul COEX Hotel, Seoul, Republic ...
(Date:11/24/2015)... ... November 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy ... , FDA has long asserted that design and manufacture of Laboratory Developed ... and do not meet the device regulations. , Come up short in an inspection ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Bolier Reactor System. Brillouin is the developer of renewable energy technologies capable of ... nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler System reactor ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... gather to share their knowledge and experiences at a live taping of the ... Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Serenity Point Rehabilitation, ... series of recent video interviews with some of the staff members at their recovery ... residential treatment facility, as well as some of the things that make their recovery ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015   HeartWare International, Inc ... less-invasive, miniaturized circulatory support technologies that are revolutionizing the ... and Chief Executive Officer Doug Godshall is ... Annual Healthcare Conference on December 1, 2015 at ... 1-2 in New York . ...
(Date:11/24/2015)... November 24, 2015 F1000Workspace - ... - since it was launched just six months ago. ... and authoring platform for scientists - since it was launched ... have been loaded on to F1000Workspace - a ... since it was launched just six months ago. ...
(Date:11/24/2015)... iRhythm Technologies, Inc. , a leading digital health care solutions ... participate in the 27th Annual Piper Jaffray Healthcare Conference at The ... . Kevin King , Chief Executive Officer of iRhythm, ... ET. --> --> About ... . --> iRhythm is a privately held digital ...
Breaking Medicine Technology: